Form 4: CervoMed CEO Reports Spouse's Stock Option Grant
Statement of Changes in Beneficial Ownership
CervoMed Inc. CEO John J. Alam filed a Form 4 disclosing an 8,150 share stock option grant awarded to his spouse, Sylvie Gregoire.
Summary
- Reporting person John J. Alam, CEO and President of CervoMed Inc., disclosed a derivative security transaction.
- The transaction involves an option to purchase 8,150 shares of common stock granted to his spouse, Sylvie Gregoire, who serves as a non-employee director.
- The exercise price for the options is $2.91 per share.
- The options vest in 1/12th increments monthly over a one-year period starting June 30, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation.
Positives
- The grant aligns the interests of a director with long-term shareholder value through equity-based compensation.
Negatives
- None identified; this is a standard compensatory equity grant for a director.
Risks
- Vesting is subject to the continued service of the director through each monthly vesting date.
Future Outlook
The options are subject to a one-year monthly vesting schedule, contingent upon the director's continued service to the company.
Management Comments
- The reporting person disclaims beneficial ownership of these securities and does not admit to being the beneficial owner for Section 16 purposes.
Industry Context
StockSavvy.ai notes that director equity grants are standard practice in the biotechnology sector to incentivize board members and align governance with shareholder interests.
Comparison to Industry Standards
- The use of monthly vesting over one year for non-employee directors is consistent with standard corporate governance practices for small-cap biotech firms.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of stock options to a non-employee director. | 06/08/2026 | Standard alignment of director incentives. |
Related Party Transactions
- The reporting person is the spouse of the director receiving the grant.
Stakeholder Impact
- Minimal impact on shareholders as this represents a standard compensatory arrangement.
Next Steps
- Monthly vesting of options beginning June 30, 2026.
Key Dates
| Date | Description |
|---|---|
| 06/08/2026 | Date of the option grant transaction. |
| 06/30/2026 | Commencement of the monthly vesting schedule. |
| 06/08/2036 | Expiration date of the stock options. |
Keywords
CervoMed, CRVO, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.